AstraZeneca (AZN) Competitors $70.49 -1.30 (-1.81%) As of 11:09 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AZN vs. NVO, NVS, SNY, GSK, TAK, ARGX, BNTX, ONC, SMMT, and TEVAShould you be buying AstraZeneca stock or one of its competitors? The main competitors of AstraZeneca include Novo Nordisk A/S (NVO), Novartis (NVS), Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), argenx (ARGX), BioNTech (BNTX), Beigene (ONC), Summit Therapeutics (SMMT), and Teva Pharmaceutical Industries (TEVA). These companies are all part of the "pharmaceutical products" industry. AstraZeneca vs. Novo Nordisk A/S Novartis Sanofi GSK Takeda Pharmaceutical argenx BioNTech Beigene Summit Therapeutics Teva Pharmaceutical Industries Novo Nordisk A/S (NYSE:NVO) and AstraZeneca (NASDAQ:AZN) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation, earnings and community ranking. Does the MarketBeat Community prefer NVO or AZN? Novo Nordisk A/S received 371 more outperform votes than AstraZeneca when rated by MarketBeat users. Likewise, 61.74% of users gave Novo Nordisk A/S an outperform vote while only 60.00% of users gave AstraZeneca an outperform vote. CompanyUnderperformOutperformNovo Nordisk A/SOutperform Votes43461.74% Underperform Votes26938.26% AstraZenecaOutperform Votes6360.00% Underperform Votes4240.00% Does the media prefer NVO or AZN? In the previous week, Novo Nordisk A/S had 16 more articles in the media than AstraZeneca. MarketBeat recorded 55 mentions for Novo Nordisk A/S and 39 mentions for AstraZeneca. AstraZeneca's average media sentiment score of 1.04 beat Novo Nordisk A/S's score of 0.62 indicating that AstraZeneca is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 27 Very Positive mention(s) 7 Positive mention(s) 11 Neutral mention(s) 5 Negative mention(s) 3 Very Negative mention(s) Positive AstraZeneca 17 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, NVO or AZN? Novo Nordisk A/S has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, AstraZeneca has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. Do institutionals and insiders believe in NVO or AZN? 11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 20.4% of AstraZeneca shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is NVO or AZN a better dividend stock? Novo Nordisk A/S pays an annual dividend of $1.63 per share and has a dividend yield of 2.5%. AstraZeneca pays an annual dividend of $2.06 per share and has a dividend yield of 2.9%. Novo Nordisk A/S pays out 49.5% of its earnings in the form of a dividend. AstraZeneca pays out 91.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Do analysts rate NVO or AZN? Novo Nordisk A/S presently has a consensus target price of $135.00, suggesting a potential upside of 102.92%. AstraZeneca has a consensus target price of $88.00, suggesting a potential upside of 22.58%. Given Novo Nordisk A/S's higher probable upside, equities research analysts plainly believe Novo Nordisk A/S is more favorable than AstraZeneca.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novo Nordisk A/S 2 Sell rating(s) 5 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.38AstraZeneca 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.10 Is NVO or AZN more profitable? Novo Nordisk A/S has a net margin of 34.81% compared to AstraZeneca's net margin of 13.01%. Novo Nordisk A/S's return on equity of 84.68% beat AstraZeneca's return on equity.Company Net Margins Return on Equity Return on Assets Novo Nordisk A/S34.81% 84.68% 26.29% AstraZeneca 13.01%32.23%12.31% Which has stronger valuation and earnings, NVO or AZN? Novo Nordisk A/S has higher revenue and earnings than AstraZeneca. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovo Nordisk A/S$290.40B1.03$14.64B$3.2920.22AstraZeneca$54.07B4.12$7.04B$2.2631.77 SummaryNovo Nordisk A/S beats AstraZeneca on 13 of the 21 factors compared between the two stocks. Get AstraZeneca News Delivered to You Automatically Sign up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AZN vs. The Competition Export to ExcelMetricAstraZenecaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$222.64B$6.89B$5.56B$7.82BDividend Yield2.96%3.05%5.11%4.22%P/E Ratio31.777.4422.5118.48Price / Sales4.12242.70395.68103.60Price / Cash11.7965.8538.1834.62Price / Book5.456.516.774.25Net Income$7.04B$143.21M$3.22B$248.23M7 Day Performance3.22%1.98%1.45%0.89%1 Month Performance-1.12%6.89%3.97%3.53%1 Year Performance-6.05%-2.52%16.14%5.08% AstraZeneca Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AZNAstraZeneca3.6197 of 5 stars$70.49-1.8%$88.00+24.8%-5.4%$218.17B$54.07B31.1383,500Earnings ReportShort Interest ↓Analyst RevisionPositive NewsGap DownNVONovo Nordisk A/S4.6323 of 5 stars$62.33+0.4%$135.00+116.6%-48.1%$279.47B$290.40B18.9354,400Upcoming EarningsAnalyst UpgradeShort Interest ↑Gap UpNVSNovartis2.4586 of 5 stars$112.84+0.6%$123.38+9.3%+16.6%$238.25B$51.72B19.18101,700Earnings ReportShort Interest ↑Positive NewsSNYSanofi3.4914 of 5 stars$52.73+0.8%$63.33+20.1%+11.6%$133.19B$44.29B21.1791,600Earnings ReportAnalyst UpgradeAnalyst RevisionPositive NewsGap UpGSKGSK1.239 of 5 stars$38.16+1.9%$40.58+6.4%-3.9%$78.70B$31.38B23.9990,100Earnings ReportAnalyst UpgradeNews CoverageTAKTakeda Pharmaceutical3.1745 of 5 stars$15.15+0.8%N/A+16.8%$48.22B$4.58T37.8947,300Upcoming EarningsNews CoveragePositive NewsARGXargenx3.2875 of 5 stars$618.09+0.5%$699.28+13.1%+71.8%$37.60B$2.19B-699.69650Upcoming EarningsPositive NewsBNTXBioNTech2.5499 of 5 stars$104.02+2.0%$143.44+37.9%+17.3%$24.99B$2.75B-49.583,080Upcoming EarningsONCBeigene2.0068 of 5 stars$250.19+2.2%$318.88+27.5%N/A$24.74B$3.81B-30.369,000Analyst ForecastAnalyst RevisionSMMTSummit Therapeutics2.681 of 5 stars$24.29+3.5%$37.50+54.4%+513.7%$17.99B$700,000.00-87.11110Analyst ForecastAnalyst RevisionGap DownHigh Trading VolumeTEVATeva Pharmaceutical Industries3.2781 of 5 stars$14.96+0.6%$23.43+56.6%+10.5%$16.95B$16.54B-10.3136,800Upcoming EarningsAnalyst UpgradeAnalyst RevisionPositive News Related Companies and Tools Related Companies Novo Nordisk A/S Alternatives Novartis Alternatives Sanofi Alternatives GSK Alternatives Takeda Pharmaceutical Alternatives argenx Alternatives BioNTech Alternatives Beigene Alternatives Summit Therapeutics Alternatives Teva Pharmaceutical Industries Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AZN) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AstraZeneca PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share AstraZeneca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.